Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and Sitagliptin [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of JNJ-38431055, sitagliptin, and their combination …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• JNJ-38431055
• Sitagliptin (sitagliptin)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED